Recent Post-Marketing Reports on Cosentyx Side Effects
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, has a well-established safety profile from clinical trials and over a decade of real-world use since FDA approval in 2015. No entirely new side effects have emerged in recent FDA updates or major pharmacovigilance reports as of 2024. Common adverse events remain infections (upper respiratory tract, candida), diarrhea, and injection-site reactions, with rare serious risks like inflammatory bowel disease (IBD) flares or hypersensitivity confirmed in post-marketing surveillance.[1][2]
What About Long-Term or Emerging Risks Patients Are Reporting?
Patient forums and FAERS database analyses show increased mentions of paradoxical reactions—like new-onset psoriasis or eczema-like rashes—potentially linked to IL-17 blockade, though these were noted in early post-approval data and not classified as novel in 2023-2024 updates. Tuberculosis reactivation risk persists, especially in endemic areas, but screening mitigates it. No spike in cardiovascular events or malignancies beyond trial baselines.[3][4]
How Do Updated Labels Reflect Changes?
The 2023 EU label revision added precautions for diverticular inflammation based on case reports, but this builds on prior IBD warnings rather than introducing a new effect. U.S. prescribing information (last major update 2022) lists no additions since 2020, emphasizing live vaccine avoidance and IBD monitoring.[2][5]
Are There Ongoing Studies or Signals to Watch?
Phase 4 trials like SUNSTONE (2023 data) confirm consistent safety with no unexpected signals after 5+ years. Novartis' 2024 safety updates report no new class-wide concerns for IL-17 inhibitors. Watch for rare uveitis cases, which occur at low rates (0.5-1%) and align with disease overlap rather than drug causation.[1][6]
Comparisons with Similar Drugs
Unlike TNF inhibitors (e.g., Humira), Cosentyx shows lower serious infection rates but higher candida risk. Versus other IL-17s like Tremfya (guselkumab), side effects overlap, with no unique Cosentyx signals emerging recently.[7]
[1]: FDA Cosentyx Label
[2]: Novartis Cosentyx Safety Overview
[3]: FAERS Public Dashboard
[4]: PubMed: Paradoxical Reactions Review (2023)
[5]: EMA Cosentyx EPAR Update
[6]: Novartis ClinicalTrials.gov SUNSTONE (NCT03934250)
[7]: DrugPatentWatch: IL-17 Inhibitors Comparison